icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
NvBjMZAfGhk2M5P4